nafamostat has been researched along with Insulin Resistance in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawashima, S | 1 |
| Kaneto, H | 1 |
| Sakamoto, K | 1 |
| Honsho, I | 1 |
| Yasuda, T | 1 |
| Kuroda, A | 1 |
| Shiraiwa, T | 1 |
| Kasami, R | 1 |
| Matsuoka, TA | 1 |
| Yamasaki, Y | 1 |
| Matsuhisa, M | 1 |
1 other study available for nafamostat and Insulin Resistance
| Article | Year |
|---|---|
Dramatic improvement of subcutaneous insulin resistance with nafamostat ointment treatment.
Topics: Benzamidines; Diabetes Mellitus, Type 2; Female; Guanidines; Humans; Hypoglycemic Agents; Injections | 2008 |